Skip to content
value.today

Medicure

MPH.V
$32 Mmarket cap on Oct 31, 2026+192.1% since Jan 2024
1M
+53.7%
Compare
World rank
#22,796
Revenue
$16 M
For year ending December-2024
Net income
$-1 M
-4.8% margin
SEC filing
Employees
—

Medicure in brief

Medicure is a listed company in the Pharmaceutical industry, based in Canada. Its market value was $32 M on 31 October 2026, which makes it the 22,796th largest listed company in the world and the 1,001st largest in Canada on this site. In the year to December 2024 it had sales of $16 M and a net loss of $1 M. Its largest business segments by sales in 2025 were Retail and Mail Order Pharmacy (70%) and Marketing and Distribution of Commercial Products (30%). Its shares trade under the symbol MPH.V (TSX Venture).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Market cap history

$0 M$14 M$28 M$42 M$56 M2020202120222023202420252026

World rank over time

▼ down 1,009 places since 2020
2020-01-01: #21837#21,83720202021-01-01: #24530#24,53020212022-01-07: #33868#33,86820222022-12-25: #31689#31,68920222023-07-30: #31365#31,36520232024-01-05: #30881#30,88120242026-09-30: #24100#24,10020262026-10-31: #22846#22,8462026

Rank in Canada: #582 (Jan 2020) · #724 (Jan 2021) · #1,725 (Jan 2022) · #1,388 (Dec 2022) · #1,224 (Jul 2023) · #1,220 (Jan 2024) · #1,177 (Sep 2026) · #1,001 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
2.0×
Price / book
2.2×
Free cash flow yield
—
Net margin (TTM)
-4.8%
Operating margin
—
Return on equity
-5.3%
Liabilities / assets
30.0%
Net debt
$42M
Revenue growth
-0.4%
R&D / revenue
14.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $21M, net income $33M$21MFY17Fiscal year ending Dec 2018: revenue $22M, net income $3M$22MFY18Fiscal year ending Dec 2019: revenue $15M, net income $-15M$15MFY19Fiscal year ending Dec 2020: revenue $9M, net income $-5M$9MFY20Fiscal year ending Dec 2021: revenue $17M, net income $-1M$17MFY21Fiscal year ending Dec 2022: revenue $18M, net income $1M$18MFY22Fiscal year ending Dec 2023: revenue $16M, net income $-1M$16MFY23Fiscal year ending Dec 2024: revenue $16M, net income $-1M$16MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$16M-0.4%—$-1M-4.8%
Dec 2023$16M-9.3%—$-1M-4.2%
Dec 2022$18M+2.2%—$1M5.9%
Dec 2021$17M+100.2%—$-1M-3.3%
Dec 2020$9M-43.0%—$-5M-59.0%
Dec 2019$15M-32.4%—$-15M-98.1%
Dec 2018$22M+7.5%$-1M$3M13.5%
Dec 2017$21M—$3M$33M160.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$1M——$-0.07—
Dec 2023$2M——$-0.07—
Dec 2022$1M——$0.10—
Dec 2021$3M——$-0.06—
Dec 2020$-2M——$-0.48—
Dec 2019$-11M——$-0.99—
Dec 2018$1M——$0.19—
Dec 2017$17M——$1.84—

SEC filings

Official filings of Medicure with the US Securities and Exchange Commission.

Annual results

Revenue
$16 M
Operating income
—
Net income
$-1 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$21 M
Total liabilities
$6 M
Total equity
$14 M

As of December-2024

Medicure scorecard#

Passes 4 of the 14 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2024; market cap of Oct 31, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.2×Price to book 2.2× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median2.0×Price to sales 2.0× against Pharmaceutical's median of 3.5×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-0.4%Revenue down 0.4% in fiscal 2024.
    • ✗Revenue up more than 5% a year over three years-2.6%-2.6% a year over the three years to fiscal 2024.
    • ✗Faster growth over three years than its peers' median-2.6%-2.6% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.07 vs -0.07Diluted EPS -0.07 in fiscal 2024 against -0.07 the year before (report's currency).
    • ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2024 against -$15 M in 2019.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2024.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2024.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-5.2%-5.2% in fiscal 2024.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Medicure's statements, beside the median of Pharmaceutical.

Medicure: main financial ratios in 2024
Ratio2024Median of peers
Net margin-4.8%-1.5%
Return on equity-5.2%-0.9%
Revenue growth, 3 years a year-2.7%2.5%
Revenue growth-0.4%7.3%

4of 7on the Piotroski tests of financial strength

  • Revenue fell 0.4% against the year before.
  • Net loss of $1 million.

Medicure: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in CAD millions; per-share figures in CAD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Medicure: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue22222322122029r27r2922
Cost of revenue8.87.77.09.06.57.34.2r3.5r3.72.3
Gross profit131416135.11325r24r2620
Research and development3.12.42.81.83.34.36.7r5.1r3.64.9
Selling, general and administrative——————20151510
General and administrative1.00.61.41.40.40.81.5r1.7r1.50.9
Total costs and expenses16151515132126r20r1915
Operating income——————−1.23.76.54.7
Interest expense and finance costs———————0.82.54.1
Income before tax−0.8−0.91.4−0.8−6.8−204.8r2.4r3.81.3
Income tax−0.3−0.0−0.0r0.0r00.10.9r−9.1r0.2r0.4
Income from continuing operations−1.0−0.91.4−0.7−6.8−203.9r11r3.61.7
Income from discontinued operations——————3.9r32r23—
Net income including minority interests−1.0−0.91.4−0.7−6.8−203.9r43r271.7
Earnings per share, basic-0.10-0.090.13-0.07-0.64-1.320.252.781.800.12
Earnings per share, diluted-0.10-0.090.13-0.07-0.64-1.320.242.391.560.11
Shares, weighted average (basic)1010101010r1516161513
Shares, weighted average (diluted)1010101010r1517181716
Balance sheet
Cash and cash equivalents7.26.44.93.72.71324r5.3r12r3.6
Receivables5.34.85.64.75.31011r8.617—
Inventory3.32.93.23.35.16.34.2r3.112—
Current assets16151513163190r11555—
Property, plant and equipment1.00.71.21.61.61.30.3r0.210—
Goodwill3.43.13.23.03.00——47—
Other intangible assets9.48.91111149.61.7r1.8101—
Non-current assets14131516181114r14160—
Total assets302830283442104r129215—
Accounts payable7.97.67.16.77.09.414r1018—
Current liabilities8.47.98.48.5121217r4462—
Long-term debt————————68—
Lease liabilities (non-current)0.50.20.50.81.10.8————
Non-current liabilities0.50.20.51.52.63.73.2r4.5115—
Total liabilities8.98.28.910.0151520r48176—
Retained earnings−67−66−65−66−66−63−50r−55−98—
Shareholders' equity———————8136—
Minority interests————————2.1—
Total equity21202118192784r81r38r4.5
Total liabilities and equity302830283442104r129215—
Cash-flow statement
Share-based compensation0.20.30.00.10.30.41.0r0.6r1.41.5
Cash from operating activities1.42.11.84.0−2.2−150.7r22r6.40.1
Intangible assets bought−0.7−0.3−0.3−0.4—−14−1.3r−0.1r——
Acquisitions, net of cash acquired————−7.2———−42—
Cash from investing activities−0.7−0.3−0.3−2.7−7.23420r54r−42−0.2
Debt issued———————0.2r0.3—
Debt repaid———————−63−1.7−0.7
Shares bought back——0—−0.5−4.1−3.0r———
Cash from financing activities−0.4−0.3−0.4−0.3−0.8−30−2.7r−83r453.1
Exchange-rate effect on cash0.600−0.0−0.0−0.61.1———
Change in cash0.81.51.21.0−10−1119−7.08.73.1
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Medicure sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Retail and Mail Order Pharmacy$15 M70%
  • Marketing and Distribution of Commercial Products$6 M30%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

How Medicure compares in Pharmaceutical

  • Market cap$32 M · higher than 10% of 393
  • Revenue$16 M · higher than 7% of 324
  • Net margin-4.8% · higher than 23% of 313
  • Revenue growth-0.4% · higher than 26% of 107
  • Price / sales2.0× · lower than 57% of 219
  • Price / book2.2× · lower than 49% of 207

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Medicure🇨🇦$32 M—-4.8%-0.4%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 31, 2026
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Medicure? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Medicure's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Medicure? Suggest a correction